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Metabolic programming controls immune cell lineages and functions, but little 
is known about gd T cell metabolism. Here, we found that gd T cell subsets 
making either IFN-g or IL-17 have intrinsically distinct metabolic requirements. 
Whereas IFN-g+ gd T cells were almost exclusively dependent on glycolysis, IL-
17+ gd T cells strongly engaged oxidative metabolism, with increased 
mitochondrial mass and activity. These distinct metabolic signatures were 
surprisingly imprinted early during thymic development, and were stably 
maintained in the periphery and within tumours. Moreover, pro-tumoural IL-17+ 
gd T cells selectively showed high lipid uptake and intracellular lipid storage, 
and were expanded in obesity, and in tumours of obese mice. Conversely, 
glucose supplementation enhanced the anti-tumour functions of IFN-g+ gd T 
cells and reduced tumour growth upon adoptive transfer. These findings have 
important implications for the differentiation of effector gd T cells and their 




T cells engage specific metabolic pathways to support their differentiation, 
proliferation and function1,2. Whereas naive ab T cells oxidize glucose-derived 
pyruvate via oxidative phosphorylation (OXPHOS) or fatty acid oxidation (FAO) 
to generate ATP, most effector ab T cells engage in aerobic glycolysis 
(“Warburg effect”), i.e. the conversion of glucose to lactate, to strengthen cell 
growth and proliferation3. On the other hand, while aerobic glycolysis is required 
for optimal ab T cell effector function4,5, tumour cells heavily consume glucose 
in the tumour microenvironment (TME), which has a dramatic impact on 
cytokine production by T cells and hampers tumour immunity5,6. There is 
therefore great interest in understanding how metabolism-based interventions 
could inhibit tumour metabolism while promoting effective anti-tumour immunity 
for improved immunotherapeutic outcomes7. 
gd T cells represent a promising immune population for next-generation cancer 
immunotherapies8,9. Since they are not MHC-restricted nor dependent on 
neoantigen recognition, gd T cells constitute a complementary layer of anti-
tumour immunity to their ab T cell counterparts10. In fact, many properties of gd 
T cells, including sensing of “stress-inducible” changes and very rapid effector 
responses, align best with innate immunity, or “lymphoid stress-surveillance”11, 
although in some instances they display adaptive-like behaviour and profound 
shaping of T cell receptor (TCR) repertoires12,13.  
The effector functions of murine gd T cells are dominated by the production of 
two key cytokines, interleukin 17A (IL-17) and interferon-g (IFN-g). Beyond 
contributions to immune responses against pathogens, the provision of these 
two cytokines by gd T cells is important in many (patho)physiological contexts, 
such as maintenance of tissue homeostasis14,15, autoimmunity16 and cancer8. 
IL-17 and IFN-g are mostly produced by distinct gd T cell subsets that, unlike 
their CD4+ T cell counterparts, typically acquire their effector functions during 
thymic development17,18. Thus, we and others have shown that thymic gd T cell 
progenitors, driven by signals including those stemming from the TCR, split into 
a CD27+ (and CD45RB+) branch that makes IFN-g but not IL-17; and a CD27- 
(and CD44hi) pathway that selectively expresses IL-1717-21.  
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The IFN-g/IL-17 dichotomy between effector gd T cell subsets is particularly 
relevant in cancer, since IFN-g-producing gd T cells (gdIFN) are associated with 
tumour surveillance and regression, whereas IL-17-secreting gd T cells (gd17) 
promote primary tumour growth and metastasis, both in mice and in humans8,22. 
However, the molecular cues that regulate the balance between such 
antagonistic gd T cell subsets in the TME remain poorly characterized. Given 
the strong impact of metabolic resources on anti-tumour ab T cell responses, 
here we have investigated the metabolic profiles of gd T cell subsets and how 
they might impact on their activities in the TME. We found that gdIFN T cells are 
almost exclusively glycolytic, whereas gd17 T cells are strongly dependent on 
mitochondrial and lipid oxidative metabolism. This metabolic dichotomy is 
established in the thymus during gd T cell development, and maintained in 
peripheral lymphoid organs and within tumours in various experimental models 
of cancer. We further show that the provision of glucose or lipids has major 
impact on the relative expansion and function of the two gd T cell subsets, and 






Intra-tumoural gd T cell subsets display distinct metabolic profiles 
The analysis of metabolic profiles of tumour-infiltrating gd T cells (gd TILs) 
presented a major challenge: the low numbers that can be retrieved from 
tumour lesions in mice are largely incompatible with techniques such as 
Seahorse metabolic flux analysis. To overcome this difficulty, we used a newly 
developed protocol, SCENITHTM (Single Cell mEtabolism by profilIng 
Translation inHibition), which is a flow cytometry-based method for profiling 
energy metabolism with single cell resolution23. This method is based on 
metabolism-dependent translation rates and puromycin’s incorporation into 
nascent proteins (Supplementary Fig. 1a). The use of specific inhibitors allows 
the estimation of glucose dependence, mitochondrial dependence, glycolytic 
capacity and fatty acid and amino acid oxidation (FaaO) capacity 
(Supplementary Fig. 1b). We employed SCENITHTM to analyze the metabolic 
profiles of gd TILs isolated from tumour lesions in well-established mouse 
models of breast (E0771) and colon (MC38) cancer (Fig. 1a). In both cancer 
models, and at both later (Fig. 1b,c) and earlier time points (Fig. 1d,e), we 
observed that gdIFN cells had substantially higher glycolytic capacity, whereas 
gd17 cells were strongly dependent on mitochondrial activity (Fig. 1b-e). These 
data, obtained in cancer models, prompted us to investigate the metabolic 
phenotypes of gd T cell subsets in multiple tissues at steady state. 
 
Peripheral gd T cell subsets show different mitochondrial and metabolic 
phenotypes 
To explore the metabolic differences between gd T cell subsets in peripheral 
tissues, we analysed mitochondria, given their central role in cellular 
metabolism. To distinguish between gdIFN and gd17 cells we used CD27 
expression18-21. CD27- gd (gd17) cells displayed increased mitotracker and 
tetramethylrhodamine methyl ester (TMRM) staining in peripheral lymph nodes 
(LNs) compared to CD27+ gd (gdIFN) cells, indicating higher mitochondrial mass 
(normalised to cell size) and mitochondrial membrane potential (ΔΨm), 
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respectively (Fig. 2a,b). These differences were retained upon activation and 
expansion in vitro over 9-days (Supplementary Fig. 2). Importantly, the distinct 
mitochondrial phenotypes were also validated with another mitochondrial 
membrane potential dye, tetramethylrhodamine ethyl ester (TMRE), and were 
features of gd17 and gdIFN cells ex vivo from multiple locations (Fig. 2c). In 
agreement with mitochondrial enrichment in gd17 cells, seahorse metabolic flux 
analysis of peripheral gd T cells showed higher levels of basal OXPHOS in gd17 
cells, and conversely, increased basal levels of glycolysis in gdIFN cells (Fig. 2d-
f). These data were validated in independent experiments using SCENITHTM 
on splenic and LN gd T cell subsets (Fig. 2g).  
To assess if this metabolic dichotomy had an underlying transcriptional basis, 
we measured the mRNA levels of key mitochondrial and glycolysis-associated 
genes in purified peripheral gd17 and gdIFN cells. We found systematic biases in 
gene expression that matched the differential metabolic programmes (Fig. 
2h,i). Of particular note is the clear-cut segregation of two master 
transcriptional regulators: Nrf1, which orchestrates mitochondrial DNA 
transcription24,25, found to be enriched in gd17 cells (Fig. 2h); and Myc, which 
controls glycolysis26,27, that was highly overexpressed in gdIFN cells (Fig. 2i). 
Myc expression was further validated using a Myc-GFP reporter mouse (Fig. 
2j). These data collectively demonstrated that gd T cell subsets possess distinct 
mitochondrial and metabolic features in peripheral organs at steady state. 
 
gd T cell subsets are metabolically programmed in the thymus 
We next aimed to understand when, during their differentiation, the metabolic 
differences between the two effector gd T cell subsets were established. Since 
most gd T cells are functionally pre-programmed in the thymus, we examined 
gd thymocyte sub-populations. Our recent studies have identified sequential 
stages of thymic gd T cell progenitor development marked by CD24, CD44 and 
CD45RB19. Early CD24+ (gd24+) precursors downregulate CD24 to become a 
CD24-CD44-CD45RB- (gdTN) population that can generate cells committed to 
either IL-17 or IFN-g expression, which display respectively CD44hiCD45RB- 
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(gd17) and CD44+CD45RB+ (gdIFN) phenotypes (Supplementary Fig 3). By 
using the SCENITHTM method, we found that, in both the adult (Fig. 3a) and 
newborn (Fig. 3b) thymus, these subsets showed the same metabolic 
dichotomy as in the periphery (Fig. 2g), although this was less distinct in gd 
thymocytes, likely due to the dynamic subset segregation process19. 
To investigate any potential switching of metabolic programming during gd 
thymocyte development, we first compared early thymic gd progenitors with 
more mature subpopulations already committed to IL-17 or IFN-g production. 
We found that gd24+ and gdTN progenitors stained highly for TMRE, that was lost 
when ΔΨm was dissipated by the ionophore carbonyl cyanide-4-
(trifluoromethoxy) phenylhydrazone (FCCP) (Fig. 3c,d). Interestingly, whereas 
gd17 cells retained a high level of TMRE staining, gdIFN cells showed a marked 
reduction in ΔΨm suggesting a metabolic switch away from OxPhos (Fig. 3d). 
Moreover, imagestream analysis of gd17 cells stained with either mitotracker or 
TMRE revealed large and active mitochondria, in contrast with gdIFN cells that 
displayed negligible staining for either dye (Fig. 3e), in line with our previous 
observations in peripheral subsets (Fig. 2a-c). Furthermore, Seahorse 
extracellular flux analysis showed that gd17 thymocytes have both higher 
maximal respiration potential and spare respiratory capacity than their gdIFN 
counterparts (Fig. 3f,g). Thus, gd T cell subsets acquire distinct mitochondrial 
features during their acquisition of effector function in the thymus. 
The adoption of divergent metabolic programs by thymic gd T cell subsets 
suggested they could thrive under distinct metabolic environments. To begin to 
address this, we placed WT E15 thymic lobes in 7-day foetal thymic organ 
cultures (E15 + 7d FTOC) with media containing either low or high amounts of 
glucose (Fig. 3h). gd17 cells were readily detected in lower glucose conditions 
but failed to develop to normal numbers when glucose concentrations were 
raised. By contrast, gdIFN cells were relatively enriched in high glucose 
conditions as demonstrated by a significant decrease in the gd17/ gdIFN cell ratio 
(Fig. 3h). We next established E15 + 7d FTOC in the presence of the glycolysis 
inhibitor 2-deoxy-D-glucose (2-DG), and found increased numbers of gd17 cells 
and increased gd17/ gdIFN cell ratios (Fig. 3i). A similar result was observed in 
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E15 + 7d FTOC when cultured with Fasentin that blocks glucose uptake 
(Supplementary Fig. 4). By contrast, running E15 + 7d FTOC in the presence 
of metformin, which reduces the efficiency of OxPhos by inhibiting complex I of 
the electron transport chain, impaired gd17 cell generation and decreased the 
gd17/ gdIFN cell ratio (Fig. 3j). Collectively, these results suggest that the 
mitochondrial characteristics adopted by gd17 and gdIFN cells during thymic 
development directly impact their ability to thrive in distinct metabolic 
environments. 
 
Distinct mitochondrial activities underlie effector fate of thymic gd T cell 
precursors 
We next aimed to investigate the association of distinct metabolic programmes 
with the developmental divergence of gd17 and gdIFN cells in the thymus. 
Although the gdTN population, i.e. the progenitor gd cell subset that immediately 
precedes the surface upregulation of either CD44 or CD45RB (marking 
commitment to the IL-17 or IFN-g pathways, respectively19) was predominantly 
TMREhi, we observed a fraction of cells with reduced TMRE staining that we 
reasoned might be transitioning to the TMRElo state shown by gdIFN cells (Fig. 
3c). We further hypothesized that the metabolic status of gdTN progenitors may 
predict their developmental fate. To test this, we sorted TMREhi and TMRElo 
cells from the gdTN subset obtained from E15 + 7d FTOC, and cultured them for 
5-days on OP9-DL1 cells that are known to support appropriate development 
of thymocytes28. As predicted, virtually all cells from the TMRElo cultures 
upregulated CD45RB and entered the IFNg-pathway (Fig. 4a); however, we 
were surprised that almost all cells from the TMREhi cultures entered the CD44hi 
IL-17-pathway (Fig. 4a). This strongly suggests that gdTN cells have already 
committed to an effector fate, and that this commitment associates with distinct 
mitochondrial activities. 
To pursue this hypothesis further, we tested gd24+ progenitors that immediately 
precede the gdTN subset; again, we observed a remarkable segregation of 
effector fate, with the majority of TMRElo gd24+ cells entering the IFNg-pathway, 
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and the majority of TMREhi gd24+ cells entering the IL-17-pathway (Fig. 4b). The 
observation that so few TMREhi gd24+ cells adopt an IFNg-secreting fate again 
suggests that most gd24+ progenitors have already committed to subsequent 
effector function. Moreover, we found that differences in TMRE levels 
correlated with the known18,20,21 effector biases of Vg1+ (gdIFN-biased) and Vg4+ 
(gd17-biased) progenitors (Fig. 4c); and validated the early TMRE-based 
segregation of effector fates using only Vg4+ progenitors (Supplementary Fig 
5). Furthermore, among gd24- thymocytes along the gdIFN pathway, we observed 
a progressive downregulation of TMRE levels from gdTN to CD44-CD45RB+ cells 
and finally gdIFN cells (Fig. 4d).  
Given that we and others20,21 have previously shown a key role for TCR 
signalling in gdIFN thymocyte differentiation, we next asked if downregulation of 
TMRE levels associated with hallmarks of TCR signalling. Indeed, we found 
that low TMRE associated with high expression of CD73 (Fig. 4e), one of the 
best established markers of TCR signalling in gd T cell development20,28,29.  
Moreover, in E15 thymic lobes, TMRE staining was reduced along with CD25 
downregulation, which is another hallmark of (developmentally early) TCRgd 
signalling18,20,21 (Fig. 4f). Furthermore, at this E15 stage, the cells with the 
lowest TMRE staining were Vg5+ progenitors (Fig. 4f) that are known to engage 
a Skint1-associated TCR-ligand in the thymus and to uniformly commit to the 
IFNg-pathway30.  
These lines of evidence suggested that gd progenitors receiving agonist TCRgd 
signals shift away from OxPhos as indicated by their reduced ΔΨm. To 
strengthen this point, we manipulated TCR signals using agonist GL3 mAb, 
which, as expected18,19, promoted gdIFN cell development while inhibiting the 
gd17 pathway in E17 + 6d FTOC (Fig. 4g). Upon specifically sorting TMREhi gd24+ 
cells from E17 thymi and stimulating them with GL3 for 5h, we found a 
subpopulation that dowregulated CD24 together with TMRE levels, in a mAb 
dose-dependent dose manner (Fig. 4h). These results strongly suggest that 
TCR signalling leads to ΔΨm downregulation as gd thymocytes differentiate into 
IFN-g producers. 
10 
To gain further molecular resolution, we performed single-cell RNAsequencing 
on TMRElo and TMREhi gd24+ cells from E15 + 2d FTOC (Fig. 4i-l). Using UMAP, 
TMRElo cells clustered clearly away from TMREhi gd24+ cells (Fig. 4j), and the 
former were enriched in genes involved in the regulation of antigen receptor 
signalling (Fig. 4k). In support of the metabolic phenotypes observed ex vivo, 
genes associated with OxPhos were enriched specifically in TMREhi gd24+ cells 
while genes involved in glucose metabolism were unregulated in TMRElo gd24+ 
cells (Fig. 4l).  
These data collectively demonstrate that metabolic status of thymic gd 
progenitors marks their developmental fate from a very early stage. Progenitors 
entering the IL-17 pathway display sustained high mitochondrial activity, 
whereas those in the IFN-g pathway undergo a TCR-induced metabolic shift 
towards aerobic glycolysis. We next questioned how these intrinsic metabolic 
differences impacted the physiology of effector gd T cell subsets. 
 
Enrichment of lipid storage and lipid metabolism in gd17 cells 
Having shown that, in stark contrast with gdIFN cells, gd17 cell generation was 
reduced under high glucose concentrations (Fig. 3h), and enhanced upon 
inhibition of glycolysis (Fig. 3i) or glucose uptake (Supplementary Fig. 4), we 
questioned whether other metabolic resources may be important for gd17 cell 
physiology. To address this question we took advantage of reporter mice 
(Zbtb16GFP) for another marker that segregates gd17 and gdIFN cells, the 
transcription factor PLZF (encoded by Zbtb16)21,14,31. We performed RNA-
sequencing of lymphoid and tissue-resident gd T cells sorted into PLZF+ (gd17) 
and PLZF- (gdIFN) cells (Fig. 5a). As expected, gd17 cells across tissues 
expressed Il17a, whereas Il17f was also expressed in tissue-resident gd17 cells 
(Fig. 5b). Different metabolic pathways were associated with lymphoid versus 
tissue resident gd T cells however, the genes common to gd17 cells across all 
tissues were related to lipid and mitochondrial metabolism, including glutamate 
transporter (Slc1a1), glucose/fatty acid metabolism (Pdk4), mitochondrial 
protein transport (Ablim3) and lipid metabolism (Fabp1, Abdh5, Atp10a). These 
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data highlight genes associated with lipid metabolism as a common feature of 
gd17 T cells across tissues. Consistent with this, LN gd17 cells had a higher 
neutral lipid content (as assessed by LipidTOX staining) than gdIFN cells (Fig. 5 
c,d). This differential lipid content was further increased upon activation with IL-
1b+IL-23 (Supplementary Fig. 6a), associated with expression of IL-17A, IL-
17F and RORgt (Supplementary Fig. 6b), and was observed across γδ T cells 
from multiple tissues, with the notable exception of the skin (Fig. 5e), where gd 
T cells have been shown to display specific mechanisms of tissue adaptation32. 
In particular, Vg6+ gd T cells in the dermis are transcriptionally distinct from 
those in pLNs and display a highly activated but less proliferative phenotype. 
This tissue adaptation may alter the metabolic requirements of skin-resident γδ 
T cells. In addition, gd T cells may adapt to utilize specific metabolites present 
within the skin33. 
Imaging analysis revealed that the increased LipidTOX staining was due to the 
accumulation of intracellular lipid droplets in gd17 cells (Fig. 5f,g). Lipid droplets 
store neutral lipids including triglycerides (TAGs) and cholesterol esters34. We 
found that the two gd subsets had equivalent TAG content (Fig. 5h) but free 
cholesterol, as determined by Filipin III staining, was higher in gd17 cells (Fig. 
5i). We next questioned if gd17 engaged in lipid uptake which could account for 
lipid storage. Using labelled palmitate (Bodipy-FL-C16), we found that gd17 cells 
selectively took up lipids (Fig. 5j), which was further enhanced following 
activation (Supplementary Fig. 6c). Analysis of gd T cell cytokine production 
confirmed that the ability to take up palmitate was specific to IL-17 producers 
(Fig. 5l,m). Of note, Vg4+ and Vg6+ (Vg1-Vg4-) gd T cells showed a higher 
palmitate uptake than Vg1+ cells (Fig. 5n); While Vg6+ gd T cells primarily 
produce IL-17, Vg4+, can produce either IFN-g or IL-1718,19. However, palmitate 
uptake was specific to Vg4+ cells that produced IL-17 (Fig. 5o). Furthermore, 
gd17 cells also displayed higher uptake of fluorescently labelled cholesterol ester 
(Bodipy CholEsteryl FL-C12) (Fig. 5k), indicating their ability to take up multiple 
types of lipids including fatty acids and cholesterol.  
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These data demonstrate that gd17 cells have an exquisite capacity to take up 
and accumulate intracellular lipids, and display transcriptional signatures of 
enhanced lipid metabolism compared to gdIFN cells. 
 
High fat diet promotes gd17 cell expansion and their accumulation in 
tumours 
We next tested the effect of a lipid-rich, high fat diet (HFD), on gd T cell subsets 
in vivo. Unlike standard fat diet (SFD) fed mice, which alternate between using 
lipids or carbohydrates for fuel during light/dark cycles respectively, feeding 
mice a HFD reduced their respiratory exchange ratio (RER), illustrating a 
systemic metabolic switch to constantly burning lipids as the main fuel source. 
(Fig. 6a). We found that both the percentage and absolute number of LN gd T 
cells were increased during HFD (Fig. 6b), which was due to a specific increase 
in gd17 (but not gdIFN) cells (Fig. 6c,d).  
Tumours are another site reported to be lipid-rich. To explore the effect of the 
lipid-rich tumour environment on gd17 cells, we employed the B16F10 
melanoma model. In SFD mice, we found an enrichment of gd17 cells within the 
tumour compared to draining LN (dLN) or spleen (Fig. 6e). These gd17 cells 
were also enriched compared to gdIFN (Fig. 6f). Given gd17 were enriched in 
obese mice and in the tumour, we next asked if obesity combined with the 
tumour model would further enhance gd17 cells. Mice fed HFD exhibited 
enhanced tumour growth (Fig. 6g), and further increased percentages and 
numbers of tumour-infiltrating gd17 cells compared to the SFD group (Fig. 6 h-
j). These data demonstrate that a lipid-rich environment selectively 
accumulates gd17 but not gdIFN cells in the tumour.  
Given the preferential uptake of cholesterol by gd17 cells (Fig. 5i), we next 
investigated its effect on gd17 cell proliferation and function. We incubated 
purified gd27- (gd17) cells for 5h with cholesterol-loaded cyclodextrin (CLC), which 
we found to promote gd27- cell proliferation when compared to control culture 
conditions (Fig. 6k). To determine its impact on tumor growth in vivo, we 
injected CLC pre-treated (or control) gd17 cells twice (within two days) into s.c. 
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E0771 tumours (as established in Fig. 1b), which allow local T cell delivery. 
Strikingly, gd17 cells pre-treated with CLC substantially enhanced tumour growth 
(Fig. 6l-n).  
Conversely, we also tested the effect of reducing lipids in vivo, by injected 
orlistat, which inhibits lipases and thus prevents uptake of dietary fat, into 
B16F10 tumour-bearing mice. Mice injected with orlistat exhibited reduced 
body weight and tumour growth compared to vehicle-treated mice 
(Supplementary Fig. 7a,b). Importantly, these mice showed decreased 
numbers of tumour-infiltrating gd17 cells, which had lower neutral lipid content 
(Supplementary Fig. 7c,d).  
Together, these data show that lipid-rich environments promote the selective 
expansion of gd17 cells that support tumour growth. 
 
Glucose supplementation enhances anti-tumour functions of gdIFN cells 
We next aimed to use the knowledge gathered in this study to boost anti-tumour 
gd T cell responses, which are known to rely on gdIFN cells8,22. Given our data 
showing that glucose promotes the development of gdIFN over gd17 cells in the 
thymus (Fig. 3h,i), and the higher glycolytic capacity of gdIFN cells in peripheral 
organs (Fig. 2g) and also within tumours (Fig. 1b-e), we hypothesized that 
glucose supplementation would enhance gdIFN cell functions. Further supporting 
this hypothesis, we found that intra-tumoural gdIFN cells preferentially took up 2-
NDBG when compared to gd17 TILs (Fig. 7a).  
We first tested the impact of glucose on gd17 and gdIFN cell functions in vitro. We 
cultured purified gd27- (gd17) or gd27+ (gdIFN) cells in standard culture conditions 
containing low dose glucose (5mM) or in high glucose (50mM). We found high 
glucose to be detrimental to gd17 cells (Supplementary Fig. 8), in stark contrast 
to gdIFN cells. Indeed, supplementation with high glucose augmented (whereas 
provision of 2-DG reduced) the percentage and numbers of gdIFN cells (Fig. 7b), 
with parallel effects on their proliferation (Fig. 7c) and on the levels of 
expression of both IFN-g (Fig. 7d) and its master transcriptional regulator21, T-
bet (Fig. 7e).  
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To specifically address the importance of aerobic glycolysis for gdIFN cells, we 
cultured gdIFN cells with galactose (compared to glucose), since cells grown in 
galactose enter the pentose phosphate pathway instead of using aerobic 
glycolysis35,36. We observed a reduction in the percentage and absolute 
numbers of gdIFN cells (Fig. 7f), as well as in their IFN-g (Fig. 7g) and T-bet (Fig. 
7h) expression levels, thus establishing that aerobic glycolysis is required for 
optimal IFN-g production by gdIFN cells. 
Next we asked if the cytotoxic function of gdIFN cells was also enhanced by 
glucose supplementation. For this, we co-cultured gdIFN cells that were 
previously supplemented (or not) with high dose of glucose with E0771 breast 
cancer cells at different effector:target (E:T) ratios. “Glucose-enhanced” gdIFN 
cells displayed substantially higher cytotoxic potency against the cancer cells, 
compared to the respective controls at each E:T ratio (Fig. 7i).  
As gd T cells are actively being pursued in the clinic as an adoptive cell therapy 
for cancer8, we tested whether we could use glucose supplementation to 
enhance the anti-tumour functions of gdIFN cells in vivo, in an adoptive cell 
transfer setting. Purified gdIFN cells were cultured in the presence or absence of 
high dose glucose for 5h, washed, and injected twice (within two days) into the 
tumour site. While control gdIFN cells produced a small yet significant reduction 
in tumour size, glucose substantially augmented the anti-tumour effects of gdIFN 
cells, essentially inhibiting tumour growth (from the time of injection) within the 
time window analysed (Fig. 7j,k). These data reveal a new, metabolism-based, 
means to enhance the anti-tumour functions of gd T cells that could be explored 
for adoptive cell immunotherapy of cancer.  
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Discussion 
Metabolism dysregulation is viewed as an immune evasion strategy in cancer. 
To overcome it, and thus enable anti-tumour immune responses, it is critical to 
understand immune cell metabolism and its interplay with tumour cells in the 
TME. Although our knowledge on ab T cell metabolism has increased 
significantly1,3,37, little is known about gd T cells. Here, we identified a metabolic 
dichotomy between the main effector gd T cell subsets that play opposing roles 
in cancer immunity8,22. Whereas anti-tumoural gdIFN cells are almost exclusively 
glycolytic, pro-tumoural gd17 cells require mitochondrial metabolism; and their 
activities within tumours can be promoted by glucose or lipid metabolism, 
respectively. 
Unexpectedly, the metabolic dichotomy of gd T cell subsets is established early 
during thymic development, which contrasts with the peripheral metabolic 
(re)programming of effector ab T cells. Naïve ab T cells require activation to 
undergo rewiring of cellular metabolism, namely transition from OxPhos to 
aerobic glycolysis, through which glucose is fermented into lactate rather than 
oxidized in mitochondria3. Furthermore, depending on metabolic cues in the 
tissue or during immune challenge, naïve T cells are pushed toward Th1, Th2, 
Th17 or Treg fates, dependent on intrinsic metabolic pathways engaged 
outside the thymus. By contrast, we show that an equivalent metabolic shift 
occurs in early thymic gd progenitors as they commit to the IFN-g pathway, 
seemingly as a result of strong TCRgd signalling. Indeed, analysis of various 
hallmarks of TCR signalling suggest that gd progenitors receiving agonist 
TCRgd signals shifted away from OxPhos as indicated by their reduced ΔΨm. 
Moreover, upon TCR (GL3 mAb) stimulation, a small population of gd 
progenitors downregulated CD24 together with ΔΨm (TMRE), thus associating 
strong TCRgd signalling in the gdIFN developmental pathway with metabolic 
reprogramming. This draws a parallel with ab T cell activation, during which 
early TCR signalling is required for induction of aerobic glycolysis38. This acts 
as a switch for Myc mRNA (and protein) expression, such that strength of TCR 
stimulus determines the frequency of T cells that transcribe Myc mRNA36. The 
common denominator of the metabolic switches in effector gd and ab T cells 
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may thus be upregulation of Myc, which is required for transcription of genes 
encoding glycolytic enzymes26,27. Indeed, our data show a striking enrichment 
of Myc (mRNA and protein) in gdIFN cells compared to gd17 cells. On the other 
hand, the sustained dependence of gd17 cells on mitochondrial OxPhos is in line 
with that recently reported for their functional equivalents in the ab T cell 
compartment, Th17 cells39. Of note, IL-17-producing type 3 innate lymphoid 
cells (ILC3) were recently shown to require both glycolysis and mitochondrial-
derived ROS for activation40, but a direct comparison with type 1 ILCs is still 
missing. 
The concept of TCR signalling playing a key role in the metabolic programming 
of gd T cell subsets builds upon, but provides a novel perspective to, previous 
models of their thymic development. Thus, the unequivocal dependence on 
strong TCR signals for gdIFN cell differentiation20,30 may be linked to a required 
metabolic shift to aerobic glycolysis. Moreover, the detrimental impact of 
agonist TCR signals on gd17 cell development may be due to metabolic conflict 
with their OxPhos requirements, documented by our FTOC experiments using 
specific inhibitors. Importantly, these distinct metabolic phenotypes are 
maintained in peripheral gd T cell subsets, which is consistent with and expands 
our previous epigenetic and transcriptional analyses41,42. 
We were particularly interested to investigate the metabolic properties of 
peripheral gd T cell subsets once they infiltrated tumour lesions, for which we 
employed three experimental models of cancer (melanoma, breast and colon). 
Critically, we found that the dichotomy between gd17 and gdIFN subsets was 
preserved in the TME, which enabled metabolic interventions that may have 
therapeutic potential. In fact, while gd T cell infiltration is largely perceived to 
associate with favourable prognosis in cancer patients43, recent clinical data 
have suggested that, in agreement with mouse experimental systems22, human 
gd17 versus gdIFN cell subsets have antagonistic prognostic values8. Thus, 
improvement in the therapeutic performance of gd T cells in the clinic44 is likely 
to require a better understanding of the factors that control the balance between 
gd17 and gdIFN cell subsets in the TME. 
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Here, we also identified lipids as key gd17-promoting factors, which is particularly 
relevant because tumours are known to be lipid-rich microenvironments4,5,45,46. 
Palmitate and cholesterol ester uptake were higher in gd17 than gdIFN cells, 
therefore we propose that increase in intracellular lipids is due to enhanced 
uptake, although endogenous lipid synthesis cannot be ruled out. Our findings 
that gd17 cell proliferation is boosted by cholesterol treatment, and that these 
cells expand substantially in obese mice, provide additional evidence that HFD 
causes a systemic increase in the gd17 subset, consistent with previous findings 
in the skin47 and lungs48, and may provide a mechanistic understanding for this 
expansion. Obesity is a known risk factor for cancer and we previously 
demonstrated the link between obesity and suppression of NK cell anti-tumour 
function49. Given that gd17 cells have strong pro-tumoural effects and we find 
this population to be expanded in tumours of obese mice, this may represent 
an additional mechanism linking cancer and obesity, whereby abundant lipids 
favor gd17 over gdIFN cells to support tumour growth. 
Conversely, we found gdIFN cells, from their thymic development to intra-
tumoural functions, to be boosted by glucose metabolism. Naturally, the large 
consumption of glucose by tumour cells7 creates a major metabolic constraint 
on gdIFN TILs. Glucose restriction can impair T cell cytokine production5,6, while 
production of lactate by tumour cells performing aerobic glycolysis can inhibit T 
cell proliferation and cytotoxic functions50. Therefore, we do not conceive 
glucose supplementation as an appropriate strategy to enhance endogenous T 
cell (including gdIFN) responses in vivo. Instead, we suggest that it should be 
considered in protocols used to expand/differentiate gd T cells ex vivo for 
adoptive cell therapy. Such an “in vitro glucose boost” may enable stronger anti-
tumour activities (namely, IFN-g production and cytotoxicity) upon T-cell 
transfer, as suggested by our data using CD27+ gdIFN cells in the breast cancer 
model, although evaluation of the duration and long-term impact of this “boost” 
requires further investigation in slower-growing tumour models. 
While we did not dissect the mechanistic link between aerobic glycolysis and 
IFN-g production by CD27+ gdIFN cells, previous studies on ab T cells have 
shown that glycolysis controls (via the enzyme GAPDH) the translation of IFN-
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g mRNA5. Moreover, glycolysis was shown to be essential for the cytotoxic 
activity of NK cells, namely their degranulation and Fas ligand expression, upon 
engagement of NK cell receptors (NKRs)51. This is particularly interesting when 
considering the potential of a human gd T cell product that we developed for 
adoptive cell therapy of cancer, Delta One T (DOT) cells9,52,53. These Vd1+ T 
cells are induced in vitro to express high levels of NKRs that enhance their 
cytotoxicity and IFN-g production52-54. We therefore propose that high dose 
glucose should be added to the DOT protocol as to further increase their anti-
tumour potential. 
In sum, this study demonstrates that thymic differentiation of effector gd T cell 
subsets, besides well-established epigenetic and transcriptional regulation, 
includes divergent metabolic programming that is sustained in the periphery 
and, in particular, in the TME. It further identifies distinct metabolic resources 
that control the intra-tumoural activities of gd T cell subsets, with lipids favoring 
gd17 cells and glucose boosting gdIFN cells, which provides a new metabolism-




All mouse experiments performed in this study were evaluated and approved 
by the institutional ethical committee (Instituto de Medicina Molecular Orbea), 
the national competent authority (DGAV) under the license number 019069, UK 
Home Office regulations and institutional guidelines under license number 
70/8758 and by the Institutional Animal Care and Use Committee of Brigham 
and Women’s Hospital and Harvard Medical School, the Trinity College Dublin 
ethics committee. Euthanasia was performed by CO2 inhalation. Anesthesia 
was performed by isoflurane inhalation.  
 
Mice and tumour cell lines 
C57Bl/6J WT mice and Myc-GFP mice (B6;129-Myctm1Slek/J) were purchased 
from Charles River and Jackson Laboratories. PLZF-GFP (Zbtb16GFP) mice 
were generated in the laboratory of D. Sant’Angelo as described previously1. 
Mice were maintained under specific pathogen-free conditions. Standard food 
and water were given ad libitum. Where indicated, mice were fed high fat diet 
(HFD) (research diets) for 8 weeks. Mice were used at the foetal (embryonic 
day 14-18), neonatal (1-5 days old) or adult (6-12 weeks old) stages. 
The E0771 murine breast adenocarcinoma cells, MC38 murine colon 
adenocarcinoma cells and B16.F10 melanoma cells were purchased from 
ATCC (Manassas, VA). Cells were maintained in Dulbecco’s Modified Eagle 
Medium (DMEM) with 10% (vol/vol) FCS (Gibco; Thermo Fisher Scientific) and 
1% (vol/vol) penicillin/streptomycin (Sigma-Aldrich). 
 
Tumour transplantation in vivo 
Mice were injected with 1 x 106 E0771 tumour cells in fat pads, 1 x 106 MC38 
tumour cells or 2 x 105 cells B16 tumour cells subcutaneously into the right 
shaved flank. Tumour growth was measured every 2-3 days using calipers and 
animals were sacrificed when tumours reached a diameter (D) of 15mm, 
became ulcerous, or 1 or 2 weeks after tumour injection. Tumour size was 
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calculated using the following formula: (D1)2 × (D2/2), D1 being the smaller 
value of the tumour diameter.  In some experiments, mice were fed with a HFD 
(60% calories from lard) for 10 weeks prior to tumour injection and the HFD was 
continued throughout the experiment.  
 
Comprehensive Lab Animal Monitoring System 
Indirect calorimetry data were recorded using a Promethion Metabolic Cage 
System (Sable Systems) essentially as described previously2. Mice were 
housed individually in metabolic chambers under a 12h light/dark cycle at room 
temperature (22oC) with free access to food and water. Mice were acclimated 
for 24h in metabolic cages before recording calorimetric variables. Mice were 
fed either a standard chow diet or a high fat (60%) diet ad libitum for 12 weeks 
prior to being placed in the metabolic cages and were maintained on either diet 
throughout the recording.  
 
Tissue processing and cell isolation  
Tumours were collected and digested with 1mg/mL collagenase Type I, 0.4 
mg/mL collagenase Type IV (Worthington) and 10 μg/mL DNase I (Sigma-
Aldrich) for 30 minutes at 37oC. Cell suspension was then filtered through a 100 
μm nylon cell strainer (Falcon/Corning). gd T cells were isolated by scratching 
thymus, spleen and lymph node on a 70µm mesh. Lungs were minced then 
homogenized in RPMI 1640 using a TissueLyser (Qiagen) and filtered through 
70µm mesh. Adipose tissue was processed as described previously3. Red 
blood cells were lysed using RBC Lysis Buffer (Biolegend) or ammonium 
chloride lysis buffer (made in-house). Single-cell suspensions of foetal and 
neonatal thymocytes were obtained by gently homogenizing thymic lobes 
followed by straining through 40µm strainers (BD).  
For cell-sorting, gd T cells were pre-enriched by depletion of CD4+ and CD8+ T 
cells, dendritic cells and B cells using biotinylated anti-CD4 (RM4-5), anti-CD8 
(53-6.7), anti-CD11c (N14) and anti-CD19 (6D5) antibodies with anti-biotin 
microbeads (Miltenyi Biotech) by QuadroMACS or gd T cells were purified using 
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TCRg/d T Cell Isolation Kit, mouse (Miltenyi Biotec). Cells were sorted on a 
FACS Aria (BD Biosciences). 
 
Cell Culture  
CD27- gd T cells were expanded in vitro as previously described4. This protocol 
was adapted to expand CD27+ gd T cells by using 10ng/ml IL-2, 10ng/ml IL-15 
and 20ng/ml IL-7. For downstream assays, gd T cells were purified using 
TCRg/d T Cell Isolation Kit, mouse (Miltenyi Biotec). Ex vivo cultures were 
performed using RPMI 1640 (Gibco) supplemented with 10% heat-inactivated 
foetal bovine serum (Gibco), 1% penicillin/streptomycin, 1% L-glutamine. For 
cytokine stimulation, cells were cultured with 10ng/ml IL-1b and IL-23 (Miltenyi 
Biotec) and/or IL-12 and IL-18 (BioLegend).  
For short-term skin-draining-lymphocyte cultures, single-cell suspensions of 
lymphocytes were isolated from skin-draining lymph nodes from adult B6 mice. 
Cells were resuspended in complete RPMI medium (RPMI-1640 with 10% 
FCS, 1% penicillin and streptomycin, and 2 mM L-glutamine). 1 x 106 
lymphocytes in 500 µl of complete medium were incubated for 48h in 48-well 
plates either under control conditions or with the addition of 5-aminoimidazole-
4-carboxamide (AICAR; 1.6 mM; Sigma-Aldrich). Cells were subsequently 
analysed by flow cytometry. 
 
Foetal Thymic Organ Cultures (FTOC)  
E15-E17 thymic lobes from B6 mice were cultured on nucleopore membrane 
filter discs (Whatman) in FTOC medium (RPMI-1640 with 10% FCS, 1% 
penicillin and streptomycin, 50 µM b-mercaptoethanol (Invitrogen), and 2 mM 
L-glutamine (Sigma-Aldrich)) for 6-12 days (unless otherwise indicated). In 
some experiments 2-deoxyglucose (2-DG; 0.6 mM), fasentin (0.6 mM), 
metformin (2 mM) or oligomycin (1 nM) were added to the cultures. All thymic 
organ cultures were subsequently analysed by flow cytometry. In some 
cultures, where concentration of glucose was manipulated, “basic” FTOC 
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medium (RPMI-1640 [-] glucose with 10% FCS, 1% penicillin and streptomycin, 
50 µM b-mercaptoethanol (Invitrogen), and 2 mM L-glutamine (Sigma-Aldrich)) 
was used, and glucose was added at 5mM for “low-glucose” conditions or 
25mM for “high-glucose” conditions. 
In some experiments, anti-TCRd antibody (GL3; 1μg/ml unless otherwise 
indicated) was added to the cultures. Cultures containing antibody were rested 
overnight in fresh FTOC medium before analysis. All thymic organ cultures 
were subsequently analysed by flow cytometry. 
 
Manipulation of gd metabolic pathways in vitro and in vivo  
Spleen and lymph nodes were harvested from C57Bl/6J mice. Cell suspensions 
were stained with LIVE/DEAD Fixable Near-IR (Thermo Fisher Scientific), anti-
CD3e (145-2C11), anti-TCRd (GL3), and anti-CD27 (LG.7F9) for 15 minutes at 
4°C. CD27+ and CD27- gd T cells were FACS-sorted. CD27+ and CD27- gd T 
cells were incubated on plate-bound anti-CD3e (145.2C11) (10 μg/mL) in the 
presence of IL-7 (50 µg/mL) or IL-7 (50 µg/mL), IL-1b (10 µg/mL) and IL-23 (10 
µg/mL), respectively. All cytokines were purchased from Peprotech. Then, cells 
were cultured with 2-Deoxy-D-Glucose (2-DG; 2mM; Sigma-Aldrich), high D-
glucose (50mM; Sigma-Aldrich), galactose (20mM; Sigma-Aldrich), Carbonyl 
cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP; 1µM; Sigma-Aldrich) 
and cholesterol-loaded cyclodextrin (CLC; 5 μg/mL) for 5h at 37°C for in vitro 
experiments. 
For experiments in vivo, purified CD27- and CD27+ gd T cells were incubated 
(or not) for 5h with cholesterol-loaded cyclodextrin (5 μg/mL) or with high D-
glucose (50mM; Sigma-Aldrich), respectively. 5 x 105 CD27- or 1 x 106 CD27+ 
gd T cells were injected twice directly at the tumor site (1st injection 7 days after 
tumour inoculation and 2nd injection 2 days later). Mice were analyzed 11 days 
after tumour cell injection. 
For lipid depletion in vivo, mice were injected daily with 50mg/kg Orlistat i.p. on 
days 6-9 after tumour injection, then tumour cell infiltrate was analysed on day 
10. 
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Killing assays for CD27+ gd T cells in vitro 
Purified CD27+ gd T cells were supplemented (or not) with high levels of glucose 
(50mM; Sigma-Aldrich) for 5h at 37°C, 5% CO2. Then, variable numbers of 
CD27+ gd T cells were co-cultured with 5 x 105 E0771 breast cancer cells in 
complete RPMI Medium (minus D-Glucose). The killing capacities of CD27+ gd 
T cells based on death of E0771 cells (Annexin V staining) was assessed by 
flow cytometry after 24h. 
 
Flow cytometry 
gd T cells were analysed by flow cytometry using standard procedures. For 
surface staining, cells were Fc-blocked with anti-CD16/32 (clone 93; 
eBioscience) and incubated for 15 minutes at 4°C with antibodies and 
LIVE/DEAD Fixable Near-IR (Thermo Fisher Scientific) or viability dye Zombie 
NIR stain (BioLegend) in FACs buffer (PBS 1X, 10% FCS, 0.5M EDTA). Anti-
CD3e (145-2C11), anti-CD27 (LG.7F9), anti-CD25 (PC61), anti-CD73 
(TY/11.8) and anti-Vg2 (UC3-10A6) were purchased from eBioscience. Anti-
CD45 (30-F11), anti-TCRd (GL3), anti-CD24 (M1/69), anti-Vg1 (2.11), anti-Vg4 
(UC3-10A6), anti-Vg5 (536) and anti-CD45RB (C363-16A) were purchased 
from BioLegend and anti-CD44 (IM7) from BD Pharmingen. Cells were washed 
with FACS buffer. For intracellular cytokine staining, cells were stimulated with 
50 µg/mL phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich) and 1 µg/mL 
ionomycin (Sigma-Aldrich) for 3-4 hours at 37°C, 5% CO2 in the presence of 10 
µg/mL brefeldin-A (Sigma-Aldrich) and 2 µM monensin (eBioscience). Cells 
were fixed and permeabilized with Foxp3 staining kit (eBioscience/Thermo 
Fisher Scientific), according to the manufacturer’s instructions. Cells were 
incubated for 30 minutes at 4°C, with the following antibodies from eBioscience: 
anti-IFN-g (XMG1.2), anti-IL-17 (TC11-18H10.1), Ki67 (16A8), T-bet (4B10) 
and RORgt (B2D). For Annexin V staining, Annexin V Kit (eBioscience) was 
used following manufacturer’s instructions.  
The following dyes were purchased from Invitrogen and stained according to 
manufacturer’s instructions: MitotrackerTM Green FM, Tetramethylrhodamine 
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Methyl Ester Perchlorate (TMRM), HCS LipidTOXTM Red Neutral Lipid Stain. 
Palmitate uptake was measured using 1µM Bodipy FL-C16 (Invitrogen) 
incubated for 10mins at 37°C. Cholesterol ester uptake was measured using 
2µM Bodipy CholEsteryl FL-C12 incubated for 1h at 37°C. Cholesterol content 
was measured using 50µg/ml Filipin III (Sigma-Aldrich) incubated for 1h at room 
temperature.  
Flow cytometry analysis was performed with a FACS Fortessa, LSRII or Canto 
II (BD Biosciences) and data analysed using FlowJo software (BD 
Biosciences). 
 
Metabolism profile of cells  
Seahorse Metabolic Flux Analysis: Real-time analysis of oxygen consumption 
rates (OCR) and extracellular-acidification rates (ECAR) of IFN-g- and IL-17-
committed gd T cells sorted from 5-day-old B6 pups and CD27+/- gd T cells from 
spleen/lymph nodes expanded in vitro were assessed using the XFp 
Extracellular Flux or Seahorse XFe-96 analyzers, respectively (Seahorse 
Bioscience). Cells were added to a Seahorse XF96 Cell Culture Microplate 
(Agilent), coated with Cell-Tak (Corning) to ensure adherence, and sequential 
measurements of ECAR and OCR were performed in XF RPMI Seahorse 
medium supplemented with glucose (10mM), glutamine (2mM), and sodium 
pyruvate (1mM) following the addition of Oligomycin A (2µM), FCCP (2µM), 
rotenone (1µM) plus antimycin A (1-4µM). Basal glycolysis, glycolytic capacity, 
basal mitochondrial respiration and maximal mitochondrial respiration were 
calculated. OCR and ECAR values were normalized to cell number. 
 
SCENITHTM  
Cells were plated at 20 × 106 cells/ml in 96-well plates. After activation of gd T 
cells, cells were treated for 30 minutes at 37°C, 5% CO2 with Control (Co), 2-
Deoxy-D-Glucose (DG; 100mM; Sigma-Aldrich), Oligomycin (O; 1µM; Sigma-
Aldrich) or a combination of both drugs (DGO). Puromycin (Puro, 10µg/ml; 
Sigma-Aldrich) is added during 15 minutes at 37°C. SCENITHTM kit 
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(http://www.scenith.com) containing all reagents and protocols were kindly 
provided by Dr. Rafael Argüello, (CIML). Cells were washed in cold PBS and 
stained with primary conjugated antibodies against different surface markers 
(as described above) for 15 minutes at 4ºC in FACS buffer (PBS 1X 5% FCS, 
2mM EDTA). After washing with FACS buffer, cells were fixed and 
permeabilized using Cytofix/Cytoperm™ (BD) following manufacturer’s 
instructions. Intracellular staining of puromycin using the anti-Puro monoclonal 
antibody (1:600, Clone R4743L-E8) was performed by incubating cells during 
30min at 4ºC diluted in Permwash. Experimental duplicates were performed in 
all conditions. 
 
In vivo glucose uptake 
2-NBDG (300µg diluted in PBS 1X; Cayman chemical) was injected i.v. in 
C57Bl/6J mice; 15min later, cells from tumours were harvested. 
 
Assessment of mitochondrial morphology  
Mitochondrial membrane potential was measured using tetramethylrhodamine, 
ethyl ester (TMRE; 100nM; Abcam) according to manufacturer protocols. 
Following TMRE staining, carbonyl cyanide-4-(trifluoromethoxy) 
phenylhydrazone (FCCP; 25µM; Abcam) was used as a positive control for 
mitochondrial membrane depolarization. Total mitochondrial mass was 
assessed using MitoTracker Green (Invitrogen) according to manufacturer’s 
instructions. All cells were subsequently analysed by flow cytometry.  
 
Triglyceride Quantification 
Triglycerides (TAGs) were quantified from expanded gd T cells in vitro using 
Picoprobe Triglyceride Quantification Assay Kit, Fluorometric (Abcam) and 




RNA isolation and real-time PCR 
mRNA was prepared from FACS-sorted CD27+ and CD27- gd T cells from WT 
spleen and draining lymph nodes using High Pure RNA Isolation kit (Roche). 
Reverse transcription was performed with random oligonucleotides 
(Invitrogen). Results were normalized to actin mRNA. qPCR was performed 
with SYBR Premix Ex Taq master mix (Takara) on an ABI ViiA7 cycler (Applied 
Biosystems). The CT for the target gene was subtracted from the CT for the 
endogenous reference, and the relative amount was calculated as 2−ΔCT.  
 
Imaging  
Thymocytes from B6 E15 thymic lobes cultured for 12 days were isolated and 
stained for surface markers and then Mitotracker Green or TMRE (as described 
above). All cells were subsequently analysed on an ImageStream™ Mark II 
imaging flow cytometer (Amnis); 30k events were saved from samples and 1k 
positive events from compensation single color controls. Analysis was 
performed using IDEAS® version 6.2.  
For lipid droplet quantification, expanded gd T cells in vitro were stained with 
LipidTOX red neutral lipid stain (Invitrogen) and Hoechst 33342 (Sigma-
Aldrich). Mitotracker Green FM (Invitrogen) was used to identify mitochondria. 
Cells were mounted onto poly-L-lysine coated slides. Images were obtained 
with a Zeiss LSM 800 confocal microscope using Zen 2.3 software (Zeiss) and 
analyzed using ImageJ. 
 
RNA-sequencing and data processing 
Single-cell sequencing libraries were generated using the Chromium™ Single 
Cell 5’ Library and Gel Bead Kit (10X Genomics) according to the 
manufacturer’s instructions. Data was analysed using the R package Seurat 
v2.35,6.  
UMI counts were normalized using regularized negative binomial regression 
with the sctransform package7. For downstream analysis of normalized data 
principal component analysis (PCA) was performed using n=50 dimensions 
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and PCA variability was determined using an Elbow plot. Differential gene 
expression analysis and GSEA was performed using the MAST and fgsea 
packages6,7. Pathways and gene lists for gene set enrichment analysis were 
obtained using the misgdbr package from Molecular Signatures database 
(MSigDB)8,9. Adaptively-thresholded Low Rank Approximation (ALRA) from the 
Seurat wrappers package was performed to correct for drop-out values for 
visualization of leading-edge and differentially expressed genes identified by 
MAST10. The accession codes for single-cell RNA sequencing are GSE150585 
and GSE156782. 
All downstream analysis was performed using R v.3.6.3 and RStudio Desktop 
1.2.5001 on an Ubuntu 19.10 linux (64 bit) system using the following R 
packages and libraries: dplyr v.0.8.5, fgsea v.1.12.0, ggplot2 v.3.3.0, MAST 
v.1.12.0, sctransform v.0.2.1, Seurat v.3.1.4, SeuratWrappers v.0.1.0, uwot 
v.0.1.8 and viridis v.0.5.1. 
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism software using non- 
parametric two-tailed Mann-Whitney test or, if both groups followed a normal 
distribution (tested by D’Agostino and Pearson normality test), using two-tailed 
unpaired Student t test or one-way analysis of variance. All data are presented 
as means ± standard error of mean (SEM) or standard deviation (SD). *p < 
0.05; **p < 0.01; ***p < 0.001, ****<0.0001.  
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Figure Legends   
Figure 1. Intra-tumoural gd T cell subsets display distinct metabolic 
profiles.  
(a) Experimental design: E0771 breast or MC38 colon cancer cell lines were 
injected in WT mice; 6 and 15 days later, tumours were extracted for metabolic 
analysis of gd T cells using SCENITHTM. Inhibitors for different metabolic 
pathways were added for 30min followed by an incubation of 15min with 
puromycin. Mean fluorescence intensity (MFI) of puromycin is analyzed by flow 
cytometry in gd17 and gdIFN subpopulations for each condition. (b-e) Puromycin 
MFI of gd17 and gdIFN T cells from E0771 (b,d) and MC38 (c,e) tumour-bearing 
mice in control conditions (Co) or after the addition of 2-deoxy-D-glucose (DG), 
oligomycin (O) or both inhibitors (DGO). Graph shows the percentage of 
glucose dependence, mitochondrial dependence, glycolytic capacity and fatty 
acid and amino acid oxidation (FaaO) capacity of tumour-infiltrating gd17 and 
gdIFN cells isolated either 6 (d,e) or 15 (b,c) days after cancer cell line injection. 
Data are representative of two independent experiments (n=5 mice per group 
in each experiment). pi: post-injection. gd17 and gdIFN T cells represents IL-17 
and IFN-g-producing gd T cells, respectively. Error bars show mean ± SEM, *p 
< 0.05; **p < 0.01; ****<0.0001 using unpaired Student’s t-test. 
 
Figure 2: Peripheral gd T cell subsets show different mitochondrial and 
metabolic phenotypes.  
(a) Representative plots (left) and summary graphs (right) of the MFI of 
mitotracker and tetramethylrhodamine methyl ester (TMRM) in gd27- (gd17) and 
gd27+ (gdIFN) T cells ex vivo from LNs of C57BL/6 mice (n=7; data pooled from 2 
experiments). (b) Representative confocal images (left) of gd17 and gdIFN T cells 
stained with mitotracker (green) and Hoechst 33342 (blue). Scale bar 
represents 5µM. Analysis of mitotracker staining relative to cell size (right) in 
gd17 and gdIFN cells ex vivo. Relative mitotracker was calculated by dividing the 
MFI of mitotracker by the MFI of FSC-A and multiplying by 100 (n=7, data 
pooled from 2 independent experiments). (c) Tetramethylrhodamine ethyl ester 
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(TMRE) MFI of gd17 and gdIFN T cells from skin draining LNs, mesenteric LNs, 
spleen and liver of WT mice. Data are representative of 3 independent 
experiments (n=3 mice per group and experiment). (d) Seahorse analysis of 
extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) of 
gd17 and gdIFN T cells (expanded in vitro) from LNs (gd17 n=2, gdIFN n=5, data 
representative of 3 independent experiments). (e) Energy map showing ECAR 
vs OCR of gd17 and gdIFN T cells. Each symbol represents average basal 
metabolism. (f) Basal glycolytic rate, glycolytic capacity and basal OxPhos of 
gd17 (n=3) and gdIFN (n=8) cell subsets (data pooled from 2 independent 
experiments). (g) Percentage of glucose dependence, mitochondrial 
dependence, glycolytic capacity and fatty acid and amino acid oxidation (FaaO) 
capacity of gd17 and gdIFN cells from spleen and draining lymph nodes (dLNs). 
Data are representative of three independent experiments (n=5 mice per group 
and per experiment). (h,i) OxPhos-related genes (Ndufa11, Ndufa13, Sdha, 
Cox6a1, Cox7a1, Cox15, Nrf1) and glycolysis-related genes (Pgm1, Pgm2, 
Gpi1, Pgam1, Myc) were measured by qPCR in purified gd17 (n=4) and gdIFN 
(n=4) T cells from spleen and dLN from WT mice. (j) Representative plot (left) 
and percentages (right) of Myc-GFP+ gd17 and gdIFN T cells from LNs of Myc-
GFP reporter mice (n=2). Error bars show mean ±  SEM or SD, *p < 0.05; **p < 
0.01; ***p < 0.001, ****<0.0001 using unpaired Student’s t-test. 
 
Figure 3: gd T cell subsets are metabolically programmed in the thymus.  
(a) Puromycin MFI of gd17 (CD44hiCD45RB-) and gdIFN (CD44+CD45RB+) T cells 
from WT adult thymus in resting conditions (Co) and after the addition of 2-
deoxy-D-glucose (DG), oligomycin (O) or both (DGO). Histogram (right) shows 
the percentage of glucose dependency (white), mitochondrial dependency 
(blue), glycolytic capacity (red) and fatty acid and amino acid oxidation (FaaO) 
capacity (purple) of thymic gd17 and gdIFN cells. Data are representative of two 
independent experiments (n=5 mice per group and per experiment). (b) 
Histograms shows the percentage of glucose dependency (white), 
mitochondrial dependency (blue), glycolytic capacity (red) and fatty acid and 
amino acid oxidation (FaaO) capacity (purple) of gd17 and gdIFN T cells from WT 
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newborn thymus (d3). Data are representative of three independent 
experiments (n=6 mice per group and per experiment). (c) Flow cytometry 
profile and Tetramethylrhodamine ethyl ester (TMRE) MFI of thymic gd24+ 
precursors treated or not with FCCP. Data are representative of 3 independent 
experiments (data points represent at least 4 lobes pooled per group and per 
experiment). (d) Flow cytometry profiles and TMRE MFI of thymic gdTN (CD44-
CD45RB-), gd17 (CD44hiCD45RB-) and gdIFN (CD44+CD45RB+) cells treated or 
not with FCCP. Data are representative of 3 independent experiments (data 
points represent at least 4 lobes pooled per group and per experiment). (e) 
Imagestream analysis of gd17 and gdIFN cells stained with either mitotracker 
green or TMRE. Data are representative of 2 independent experiments. (f) O2 
consumption rates (OCR) of gd17 and gdIFN cells were measured by Seahorse 
analysis in real-time under basal conditions and in response to indicated 
mitochondrial inhibitors. (g) Histograms show maximal respiration potential and 
spare respiratory capacity by measuring oxygen consumption rates (OCR) of 
gd17 and gdIFN cells from thymuses of 5-day old B6 pups. Data are representative 
of 3 independent experiments (pooled thymic lobes from n>10 mice per group 
per experiment). (h-j) Flow cytometry profiles of thymic gdTN, gd17 and gdIFN cells 
from 7-day FTOC of E15 thymic lobes either with media containing low (5mM) 
or high (25mM) glucose (h), or with or without 2-deoxy-d-glucose (2-DG) (i) or 
metformin (j). Histograms show the number of gd17 cells and gd17/gdIFN cell ratio. 
Data are representative of 2 (h) or 3 (i-j) independent experiments (at least 4 
lobes pooled per group per experiment). Error bars show mean ± SEM or SD, 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 using unpaired Student’s t-
test.  
  
Figure 4: Distinct mitochondrial activities underlie effector fate of thymic 
gd T cell progenitors.  
(a,b) Flow cytometry profiles and percentage of thymic gd17 and gdIFN cell output 
from post-sorted TMRElo and TMREhi gdTN cells (a) or gd24+ cells (b) after 5-day 
culture on OP9DL1 cells. Data are representative of 3 independent experiments 
(n = 4 mice pooled per group per experiment). (c) Percentage of Vg1+ and Vg4+ 
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cells in TMRElo and TMREhi gd24+ and gd24- subsets. Data are representative of 
3 independent experiments (cells sorted from n=4 mice pooled per group per 
experiment). (d) TMRE MFI of thymic gdTN (CD44-CD45RB-), CD24-CD44-
CD45RB+ gd T cells and gdIFN cells (CD44+CD45RB+)  from 6-day FTOC of E17 
B6 thymic lobes. (e) TMRE staining in CD24-CD73+, CD24-CD73-, 
CD24+CD73+ and CD24+CD73- gd T cells from 7-day FTOC of E15 B6 thymic 
lobes. (f) TMRE staining in CD25-CD24+ (gd24+ cells), CD25med, CD25hi and 
Vg5+ gd progenitors from E15 thymus. (g) Flow cytometry profiles of thymic gdTN, 
gd17 and gdIFN cells from 6-day FTOC of E17 B6 thymic lobes stimulated or not 
with anti-TCRd mAb (GL3; 1μg/ml). Graph shows percentage of gd17 and gdIFN 
cells in each condition. (h) FACS-sorted gd24+TMREhi cells from E17 thymi were 
cultured (or not) for 5h with different concentrations (as indicated) of anti-TCRd 
mAb (GL3). TMRE levels were analysed by flow cytometry in gd24- and gd24+ 
cells. Data are representative of 3 independent experiments (n=4 mice pooled 
per group per experiment). (i) Experimental design for single-cell RNAseq (10x 
Genomics) on TMRElo  and TMREhi gd24+ cells  from E15 + 2d FTOC. (j) 
Clustering of single TMRElo and TMREhi gd24+ cells using UMAP. (k) GO term 
analysis of genes upregulated in TMRElo versus TMREhi gd24+ cells. (l) Heatmap 
of differentially upregulated genes from comparison of TMRElo and TMREhi 
gd24+ cells. Genes are grouped in relation to their function in either OxPhos or 
glucose metabolism. Error bars show mean ± SD, *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001 using unpaired Student’s t-test.  
 
Figure 5. gd17 cells show higher lipid uptake and lipid droplet content than 
gdIFN cells. 
(a) Experimental set up for bulk RNA-sequencing of PLZF+ (gd17) and PLZF- 
(gdIFN) cells isolated from PLZF-GFP (Zbtb16GFP) mice. (b) Quadrant plot of 
genes upregulated in tissue resident PLZF+ gd T cells (lower right), lymphoid 
PLZF+ gd T cells (upper left), PLZF+ gd T cells from all tissues (upper right) or 
PLZF- gd T cells from all tissues (lower left).  (c) Representative histogram of 
neutral lipid staining (LipidTOX) in ex vivo gd17 (CD27-) and gdIFN (CD27+) cells 
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from LNs. (d) LipidTOX MFI in gd17 and gdIFN cells ex vivo from LNs as shown 
in (a) (n=11, data pooled from 3 independent experiments). (e) LipidTOX MFI 
in gd17 and gdIFN cells from spleen, LNs, lungs, adipose, liver and skin (n=5-8, 
data pooled from 2 independent experiments). (f) Confocal imaging of gd17 and 
gdIFN cells expanded in vitro and stained with LipidTOX (red) and Hoechst 
33342 (blue). Scale bar represents 5µM (data representative of a minimum 10 
images from 2 independent experiments). (g) Quantification of confocal 
imaging as shown in (d) (each data point represents the average per cell per 
image). (h) Quantification of triglyceride (TAG) levels from gd17 and gdIFN cells 
expanded in vitro (n=7, each symbol represents one biological replicate). (i) 
Filipin III staining of gd17 and gdIFN cells ex vivo from LNs. Representative 
histogram (left) and MFI (right) (n=6, data pooled from 2 independent 
experiments). (j) Representative histogram of Bodipy-FL-C16 uptake in gd17 and 
gdIFN cells from LNs ex vivo (n=8, data pooled from 2 independent experiment). 
(k) Representative plots of Bodipy-FL-C16 uptake and IL-17 or IFN-g production 
by gd17 and gdIFN cells from LNs stimulated with PMA/ionomycin. (l) Bodipy-FL-
C16 MFI in IFN-g+ and IL-17+ gd T cells (n=4, data representative of 3 
independent experiments). (m) Representative plot of Vg1 and Vg4 expression 
in total gd T cells and percentage Bodipy-FL-C16 uptake by LN gd T cell subsets 
(Vg1+, Vg4+, Vg1-4-) (n=6, data pooled from 2 independent experiment). (n) 
Representative IFN-g and IL-17 production by Vg4+ gd T cells from LNs and 
percentage Bodipy-FL-C16 uptake by Vg4+IFN-g+ and Vg4+IL-17+ gd cells (n=6, 
data pooled from 2 independent experiments). (o) Percentage Bodipy 
CholEsteryl FL-C12 uptake by gd17 (CD27-) and gdIFN (CD27+) cells from LNs ex 
vivo (n=6, data pooled from 2 independent experiments). Error bars show 
mean ±  SD, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 using unpaired 





Figure 6. High fat diet promotes the expansion of gd17 cells in lymph nodes 
and within tumours. 
(a) Respiratory exchange ratio (RER) of mice fed SFD or HFD for 8 weeks (n=3, 
data from 1 experiment). (b) Bar graphs showing the percentage and absolute 
numbers of CD3+ gd T cells from LNs of standard fat diet (SFD) and high fat 
diet (HFD) mice (n=9, data pooled from 3 independent experiments). (c) 
Proportion of gd17 (CD27-) and gdIFN (CD27+) T cells in LNs of SFD and HFD fed 
mice (n=9, data pooled from 3 independent experiments). (d) Percentage and 
absolute numbers of CD27+ IFN-g+ and CD27- IL-17+ gd T cells from LNs of SFD 
and HFD mice (n=9, data pooled from 3 independent experiments). (e) 
Proportion of infiltrating gd17  cells in spleen, draining LN and tumour in the B16 
tumour model (dLN and tumour n=30, data pooled from 4 independent 
experiments, spleen n=7, naïve LN n=5).  (f) Bar graph showing the percentage 
of gd17 and gdIFN cells infiltrating tumours (n=9, data pooled from 2 experiments). 
(g) Bar graph represents the size of tumours (mm3) in SFD and HFD fed mice. 
(h) Bar graph showing proportion of infiltrating gd17 (CD27-) and gdIFN (CD27+) 
cells in tumours of SFD and HFD fed mice (SFD n=10, HFD n=12, data pooled 
from 2 independent experiments). (i) Representative plots of IL-17 and IFN-g 
expression in gd T cells infiltrating tumours of SFD and HFD fed mice. Bar 
graphs represent  the percentage of gd17 and gdIFN cells infiltrating tumours (SFD 
n=17, HFD n=20, data pooled from 3 independent experiments). (j) Bar graph 
showing the number/mm3 of gd17 and gdIFN cells in tumours of mice on SFD or 
HFD (SFD n=7, HFD n=8, data pooled from 2 independent experiments). (k) 
Plots of proliferating Ki67+ gd17 cells cultured for 5h with or without cholesterol-
loaded cyclodextrin (CLC). Graph represents the percentage of Ki67+ gd17 cells 
(data are representative of two independent experiments; pool of 3-5 mice per 
experiment).  (l) gd17 cells cultured (or not) with cholesterol-loaded cyclodextrin 
(CLC) for 5h were injected s.c. into E0771 tumours at d7 and d9 after tumour 
cell injection. Representative picture of tumours observed at day 11 post-E0771 
cell inoculation. (m) Graph showing tumour weight at day 11 post-E0771 
inoculation. (n) E0771 tumour growth was monitored every two days after 
inoculation ((l-n) data are representative of three independent experiments 
42 
(pool of 2-5 mice per experiment). Error bars show mean ±  SD, *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001 using unpaired Student’s t-test or 
ANOVA test.  
  
Figure 7: Glucose supplementation enhances the effector functions of 
gdIFN cells.  
(a) Glucose uptake assessed upon i.v. injection of fluorescent 2-NBDG in 
tumour-bearing mice. Tumours were harvested 15 min later for analysis. 
Histogram represents 2-NBDG uptake in gd17 and gdIFN cells. (b-i) Purified 
splenic and peripheral lymph nodes gdIFN T cells (CD3+TCRgd+CD27+) were 
cultured in the presence of IL-7 with media containing low glucose (5mM), 2-
deoxyglycose (2-DG), high glucose (50mM) or galactose (20mM) for 78h. (b) 
Plots of peripheral gdIFN T cells cultured with IL-7 and media containing low 
glucose, 2-DG or high glucose. Histogram represents the fold change in 
number of gdIFN T cells cultured with 2-DG or high glucose versus low glucose. 
(c) Fold change in number of proliferating Ki-67+ gdIFN cells cultured with 2-DG 
or high glucose versus low glucose. (d,e) IFN-g (d) and T-bet (e) expression 
was analysed by flow cytometry in gdIFN cells incubated with media containing 
low glucose, 2-DG or high glucose. Histograms show the MFI of IFN-g and T-
bet. (f) Flow cytometry profiles of peripheral gdIFN T cells cultured with IL-7 and 
media containing glucose (50mM) or galactose (20mM). Histogram represents 
the numbers of gdIFN T cells. (g,h) IFN-g (g) and T-bet (h) expression was 
analysed by flow cytometry in gdIFN cells incubated with media containing 
glucose or galactose. Histograms show the MFI of IFN-g and T-bet. 
(i) Representative histograms and summary of killing assay in vitro 
of E0771 tumour cells by gdIFN T cells previously supplemented (or not) with 
glucose (5h pre-incubation). (j) Representative picture of tumours observed at 
day 11 post-E0771 inoculation. gdIFN cells supplemented (or not) with glucose 
for 5h were injected into the tumour at d7 and d9 after tumour cell injection. (k) 
The E0771 tumour growth was monitored every two days during 11 days after 
E0771 inoculation (data are representative of two (i-k) or four (b-h) 
independent experiments; n = 5-10 mice per group and per experiment). Error 
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bars show mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 using 
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Supplementary Figure 1: SCENITHTM methodology for analysis of cell metabolism.
SCENITHTM assesses the impact of metabolic inhibitors on protein synthesis. Mean
fluorescence intensity (MFI) of Puromycin is analysed in each condition (Co: control-no
inhibition ; DG: 2-deoxyglucose inhibiting glycolysis ; O: oligomycin inhibiting OxPhos and DGO:
DG+O inhibitors). Bottom graph shows glucose dependence (white), mitochondrial dependence
(blue), glycolytic capacity (red), and fatty acid and amino acid oxidation capacity (purple), which










































































































Glucose dependence (%): 100*((Co-DG)/(Co-DGO) 
Mitochondrial dependence (%): 100*((Co-O)/(Co-DGO) 
Glycolytic capacity (%): 100 – Mitochondrial dependence
























DGO: DG + Oligomycin






















































γδ17 T cells γδIFN T cells
Supplementary Figure 2: γδ17 and γδIFN cells expanded in vitro retain their mitochondrial
and lipid phenotypes. (a) Representative flow plots of CD3 and TCRδ expression on γδ17 and γδIFN
cells expanded in vitro from total spleen/LN cells. (b) CD27 expression on in vitro expanded γδ17 and
γδIFN cells. (c) IL-17 and IFNγ production by in vitro expanded γδ17 and γδIFN cells respectively, following
activation with PMA/ionomycin. (d) Vγ1 and Vγ4 expression on γδ17 and γδIFN cells expanded in vitro.
(e) Representative staining of γδ17 and γδIFN cells expanded in vitro for mitotracker, TMRM, lipidTOX and
Bodipy-FL-C16. (f) MFI of mitotracker, TMRM, lipidTOX and Bodipy-FL-C16 staining on γδ17 and γδIFN cells
expanded in vitro. n=3, data representative of 3 independent experiments. Error bars show mean + SD,









































































































γδ17 γδIFN γδ17 γδIFN
γδ17 γδIFN γδ17 γδIFN γδ17 γδIFN γδ17 γδIFN
Supplementary Figure 3: γδTN cells can generate γδ17 and γδIFN cells. Flow cytometry
profiles of thymic γδ T cells from E15 thymic lobes that had been cultured for 7-days in fetal
thymic organ culture (E15 + 7d FTOC). CD24+ (γδ24+) precursors downregulate CD24 to
become a CD24-CD44-CD45RB- (γδTN) population. γδTN cells are able to become either IL-17-











































Supplementary Figure 4: Thymic γδ17 cells are increased upon inhibition of glucose
uptake. Flow cytometry profiles of thymic CD24- γδ T cells further gated as γδTN (CD44-
CD45RB-), γδ17 (CD44hiCD45RB-) and γδIFN (CD44+CD45RB+) cells from E15 thymic lobes in
7-day FTOC with media containing (or not) Fasentin. Histograms show the number of γδ17
cells and γδ17/γδIFN ratio. Data are representative of 2 independent experiments (at least 4
lobes pooled per group per experiment). Error bars show mean ± SEM, **p < 0.01,
****p < 0.0001, using unpaired Student’s t-test.


















































Supplementary Figure 5: Mitochondrial activity identifies Vγ4+ progenitors with distinct
effector fates at very early stages. (a) Flow cytometry profiles and percentage of thymic
γδ17 and γδIFN cell output from post-sorted TMRElo and TMREhi Vγ4+γδ24+ cells after 5 days of
culture on OP9DL1. Data are representative of 3 independent experiments (cells sorted from
n=4 mice pooled per group per experiment). (b) Flow cytometry profiles for sorted TMREhi and
TMRElo Vγ4+γδ24+ cells (left) that were then cultured on OP9-DL1 cells for a further 5-days
(right plots). Histogram shows the percentage cell output from sorted γδTNVγ4+ TMRE hi/lo



































































































Supplementary Figure 6. Enriched lipid metabolism and higher lipid uptake in γδ17 cells.
(a-b) Feature plots of OxPhos-related (a) or lipid-related (b) genes from single-cell RNA
sequencing of adipose γδ T cells. Cell clusters based on CD27 expression. (c) LipidTOX MFI in
γδ17 (CD27-) and γδIFN (CD27+) cells from LN cells activated in vitro with IL-1β+IL-23 and IL-
12+IL-18 respectively. n=9, data pooled from 3 independent experiments. (d) Representative
plots of LipidTOX staining and IL-17A, IL-17F or RORγt expression in γδ27- cells from LNs
activated in vitro with IL-1β+IL-23 for 6h. Data representative of 3 independent experiments. (e)
Bodipy-FL-C16 MFI in γδ17 (CD27-) and γδIFN (CD27+) cells unstimulated or stimulated in vitro with
IL-12+IL-18 or IL-1β+IL-23.(n=3, data from 1 experiment). Error bars show mean + SD,














































































































































Inhibition of dietary fat uptake reduces tumour growth and γδ17 cells in the tumour.
B16F10-tumour bearing mice were given daily injections of either vehicle or orlistat on
days 6-9, and tumours were analysed on day 10. (a) Percentage body weight following
tumour cell injection; arrows indicate when orlistat or vehicle were administered. (b)
Tumour volume on days 8-10 following B16F10 inoculation. Absolute numbers (c) and

























































































































































































































Glucose supplementation diminishes γδ17 cell numbers and proliferation. (a)
Flow cytometry profiles of peripheral γδ17 T cells cultured with media containing low
(5mM) or high (50mM) doses of glucose. Graph depicts total numbers of γδ17 T cells.
(b) Number of proliferating Ki-67+ γδ17 T cells cultured with low or high glucose. Data
are representative of three independent experiments (n =3-5 mice per group and per
experiment). Error bars show mean ± SEM, **p < 0.01, using unpaired Student’s t-test.
